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Background: Chagas’ disease, caused by the protozoan parasite Trypanosoma cruzi, needs urgent alternative
therapeutic options as the treatments currently available display severe limitations, mainly related to efficacy
and toxicity.
Objectives: As phosphodiesterases (PDEs) have been claimed as novel targets against T. cruzi, our aim was
to evaluate the biological aspects of 12 new phthalazinone PDE inhibitors against different T. cruzi strains and
parasite forms relevant for human infection.
Methods: In vitro trypanocidal activity of the inhibitors was assessed alone and in combination with benznida-
zole. Their effects on parasite ultrastructural and cAMP levels were determined. PDE mRNA levels from the
different T. cruzi forms were measured by quantitative reverse transcription PCR.
Results: Five TcrPDEs were found to be expressed in all parasite stages. Four compounds displayed strong effects
against intracellular amastigotes. Against bloodstream trypomastigotes (BTs), three were at least as potent
as benznidazole. In vitro combination therapy with one of the most active inhibitors on both parasite forms
(NPD-040) plus benznidazole demonstrated a quite synergistic profile (xR FICI = 0.58) against intracellular amas-
tigotes but no interaction (xR FICI = 1.27) when BTs were assayed. BTs treated with NPD-040 presented disrupted
Golgi apparatus, a swollen flagellar pocket and signs of autophagy. cAMP measurements of untreated parasites
showed that amastigotes have higher ability to efflux this second messenger than BTs. NPD-001 and NPD-040
increase the intracellular cAMP content in both BTs and amastigotes, which is also released into the extracellular
milieu.
Conclusions: The findings demonstrate the potential of PDE inhibitors as anti-T. cruzi drug candidates.
Introduction
About 8 million people are infected with the protozoan parasite
Trypanosoma cruzi, the aetiological agent of Chagas’ disease,
which is the main cause of infectious cardiomyopathy in Latin
America.1 Introduced 50 years ago into clinical practice, the
nitroheterocyclic compounds benznidazole and nifurtimox are still
the only therapeutic options, despite serious concerns such as:
limited efficacy, especially in the chronic phase; the occurrence of
naturally resistant parasite strains; and intense adverse effects,
often leading to treatment cessation.2,3
Phosphodiesterases (PDEs) are a group of highly conserved
hydrolases that control the intracellular levels of cyclic nucleotides
by hydrolysing the second messengers cAMP and/or cGMP, both in
mammalian hosts4 and parasites.5 The high level of conservation
between PDEs from mammalians and trypanosomatids could be
advantageous6,7 as PDEs are already a pharmacological target
in humans and some of the parasite homologues are essential.8
In kinetoplastids, four families of class I PDEs (A–D) have been
identified9,10 and the enzymes are involved in essential functions
including cell division, osmoregulation and virulence.10–14
VC The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
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The Trypanosoma PDEs were pharmacologically validated as a
therapeutic target for Trypanosoma brucei using the tetrahydroph-
thalazinone NPD-001 (previously known as Cpd A).14 It induced a
dose-dependent increase in the cAMP intracellular content in
bloodstream forms, leading to immediate inhibition of prolifer-
ation and a complete loss of viability 72 h after drug exposure,14
similarly to the phenotype observed upon RNAi knockdown of the
TbrPDE-B1 and TbrPDE-B2 genes.10 The tetrahydrophthalazinones
have now been established as a promising antiparasitic scaffold.
Novel NPD-001 analogues have been evaluated for effects on
parasite viability and for their inhibition of TbrPDE-B1. Small struc-
tural variations were shown to lead to drastic potency differences
against human and T. brucei PDE subtypes, likely due to the
presence of the parasite-specific P-pocket next to the conserved
substrate binding site.15–18
The aim of this study was to evaluate the activity and select-
ivity of NPD-001 and a further 11 phthalazinone derivatives
against T. cruzi, using a well-established screening flow chart
based on the Target Product Profile for Chagas’ disease,19
followed by an in vitro exploration of combination therapy with
benznidazole. Effects of selected inhibitors on ultrastructure
and cAMP levels were determined and the mRNA levels of PDEs
in amastigotes, epimastigotes and bloodstream forms were
evaluated. The findings support the targeting of PDEs for drug
discovery against Chagas’ disease.
Materials and methods
PDE inhibitors and drugs
Stock solutions (10 or 20 mM) of 12 compounds (Figure 1) were prepared in
DMSO (1% maximum final concentration). Benznidazole (Laboratório
Farmacêutico do Estado de Pernambuco, Brazil) was used as a reference
drug.20 Identity and purity information is provided for most active com-
pounds on bloodstream trypomastigotes (BTs) and/or intracellular
forms, i.e. NPD-001, NPD-040, NPD-048, NPD-223, NPD-1015 and NPD-
1016 (Table S1, available as Supplementary data at JAC Online).
Mammalian cells
Primary cardiac cell (CC) and L929 fibroblast lineage cultures were obtained
as reported previously.21,22
Parasites
BTs of Y [Discrete Typing Unit (DTU) II] and Colombiana (DTU I) strains of
T. cruzi were obtained by cardiac puncture of infected Swiss Webster mice
at peak parasitaemia.21,23 Trypomastigotes of the Tulahuen strain (DTU VI)
expressing the Escherichia coli b-galactosidase gene were maintained as
reported previously.20 Extracellular amastigotes of the Y strain were
obtained from the supernatant of infected cultures of CCs (50:1, parasite:-
host cell) as reported previously.24 Epimastigotes of Y and Colombiana
strains were cultivated using a routine method.23
Figure 1. Chemical structure of the phthalazinones used in this study. MW: molecular weight; CLogP, calculated octanol–water partition coefficient;
PSA, polar surface area.
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Cytotoxicity assays
Non-infected CC and L929 cultures were incubated at 37C for 24–96 h with
increasing concentrations of each compound (up to 200 lM) diluted in
RPMI. Cellular viability was determined by the PrestoBlue (CC) and
AlamarBlue (L929) tests and the morphology and spontaneous contracti-
bility of CCs were evaluated by light microscopy. The results were expressed
as the difference in reduction between treated and non-treated cells. LC50
values (concentration reducing the labelling related to cellular viability by
50%) were determined by non-linear regression (sigmoid curve).20
Trypanocidal activity
BTs of the Y strain (5%106 parasites/mL) were incubated for 2 and 24 h at
37C in RPMI in the presence or absence of 1:3 serial dilutions (six points) of
the compounds (0–200 lM) for direct quantification of live parasites by light
microscopy, for calculation of the EC50 (compound concentration that
reduces the number of parasites by 50%).20 For the analyses of compound
effects on intracellular forms, T. cruzi-infected L929 cultures (Tulahuen
strain) were incubated for 96 h at 37C with each compound at non-toxic
concentrations (six points) followed by calculation of EC50, as reported.
23
For extracellular amastigotes of the Y strain, the parasites were incubated
(5%106/mL) with increasing concentrations of the selected compounds for
24–96 h and the EC50s determined through direct quantification by light mi-
croscopy.24 The selectivity index (SI) is the ratio between LC50 (toxicity for
mammalian cells) and the EC50 (activity against the parasite). The pEC50
represents the negative log of the EC50 value {#log[EC50 (M)]}.
In vitro combination therapy
Drug interactions were investigated in the Tulahuen strain of T. cruzi using a
fixed-ratio method25 by combining the selected compound with benznida-
zole, following 96 h of incubation at 37C. Predetermined EC50 values were
used to determine the top concentrations of the individual ratios ensuring
that the EC50 fell in the midpoint of a 7-point 2-fold dilution series. The fixed
ratios of 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 were used, as previously reported.26
Determination of FIC index (FICI), classification of
interaction and isobologram construction
FICIs and the sum of the FICIs (RFICI) were calculated using the following
formula: FICI of tested compound = EC50 of tested compound in combin-
ation/EC50 of tested compound alone. The same equation was applied to
benznidazole and RFICI = FICI (inhibitor) ! FICI (benznidazole). An overall
mean RFICI was calculated for each combination and used to classify the
nature of the interaction, as follows: ‘synergy’ for xRFICI0.5, ‘antagonism’
for xRFICI >4.0 and ‘no interaction’ or ‘additive’ for xRFICI >0.5–4.0 (xRFICI
indicates the overall mean RFICI).27 Isobolograms were constructed by
plotting the EC50 of NPD-040 against the EC50 of benznidazole.
26
Cloning of TcrPDEs
Genomic DNA was extracted from Y and Colombiana strain parasites. To as-
certain the correct start and stop sequences for the five genes, PCRs first
amplified from the untranslated regions flanking each gene, either to pri-
mers within the genes (PDEs B1, B2 and C) or across the coding region (PDEs
A and D), using a proofreading polymerase (Phusion; NEB, Hitchin, UK; pri-
mers in Table S2). Amplified fragments were ligated into the pGEM-T Easy
subcloning vector (Promega, Southampton, UK) and Sanger sequenced
(Source BioScience). This sequence information was used to design primers
to amplify the complete coding sequence for each PDE from both Y strain
and Colombiana genomic DNA, again using Phusion polymerase (Table S2),
followed by ligation into pGEM-T Easy and Sanger sequencing. All sequen-
ces were submitted to GenBank (Table S3).
qRT–PCR
Samples of T. cruzi Y strain epimastigotes, BTs and amastigotes collected
from the supernatant of infected CC cultures were stabilized in RNAlater
(Thermo Fisher). RNA was extracted using a Macherey-Nagel NucleoSpin
RNA extraction kit and cDNA produced using Superscript III reverse tran-
scriptase (Thermo Fisher). The expression profile of each of the five T. cruzi
PDEs was generated from the three-stage cDNAs. GoTaq qPCR master mix
(Promega) was used to amplify fragments, with an Applied Biosystems
7500 Real Time PCR System (primers in Table S2). The expression levels
were calculated relative to the T. cruzi housekeeping gene GAPDH as a con-
trol (primers from Silber et al.28).
Electron microscopy
BTs from the Y strain (5%106 parasites/mL) were treated with the selected
compound for 2 h at the EC50 concentration. The parasites were fixed with
2.5% glutaraldehyde and processed as routine for transmission (TEM) and
scanning (SEM) electron microscopy.29
cAMP measurement
Extracellular amastigotes (2%107 parasites/mL) or BT forms of Y strain
(1.5%107 parasites/mL) were treated with NPD-001 or NPD-040 at a con-
centration of 2% EC50 for 2.5 h at 37C, processed and analysed using a
cAMP ELISA kit (Cayman Chemicals, MI, USA).14
Statistical analysis
Statistical analysis was performed using Student’s t-test with the level of
significance set at P0.05.
Ethics
All animal procedures performed at Fundaç~ao Oswaldo Cruz (FIOCRUZ)
were carried out in accordance with the guidelines established by the
Committee of Ethics for the Use of Animals (CEUA LW16/14).
Results
Phenotypic screening of potential PDE inhibitors against
relevant T. cruzi forms
Compounds assayed for activity against intracellular forms of the
b-galactosidase-transfected Tulahuen strain (DTU VI) showed that
4 out of 12 inhibitors exhibited EC50 values up to 10lM, established
as the threshold for hit compounds for T. cruzi.30 However, none of
them presented better activity or superior selectivity than benzni-
dazole (EC50 = 2.7±0.4 lM, SI = 51) in this system (Table 1). To
evaluate the effect against another very relevant parasite form
and DTU for mammalian infection, additional phenotypic
approaches were conducted using BTs from the Y strain (DTU II).
In these assays, three compounds were at least as active as benz-
nidazole: NPD-001 (PDE inhibitor reference compound), NPD-040
and NPD-048. The latter was twice as potent as benznidazole, with
EC50 values of 6.25±0.68lM and 12.9±1.9 lM, respectively, after
24 h of incubation at 37C; the NPD-040 EC50 was 12.1±0.8 lM
(Table 2). For NPD-223, NPD-1015 and NPD-1016, major differen-
ces in potencies were observed depending on the parasite form,
with EC50 values from 5.1–9.4 lM or from 54 up to >200 lM for
intracellular (Tulahuen strain) and BT (Y strain) forms, respectively
(Tables 1 and 2).
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NPD-040 (one of the most active against both parasite forms
and strains) and benznidazole were further assayed against free
amastigotes of the Y strain obtained from the supernatant of
T. cruzi-infected CC cultures after host cell rupture induced by
superinfection. Benznidazole and NPD-040 presented a time-
dependent effect, with the latter acting faster, reaching EC50 val-
ues diminishing from 7.7 to 4 lM after 24–96 h of PDE inhibitor
exposure (Figure 2).
Exploration of combinations with benznidazole
As combinatory approaches represent an interesting strategy of
improving efficacy by tackling distinct targets with multiple drugs,
a fixed-ratio combinatory assay was performed using NPD-040
and benznidazole, due to its consistent anti-T. cruzi behaviour.
Using the classification proposed by Odds,27 the xRFICI values for
the benznidazole and NPD-040 combination revealed a profile
close to synergy against intracellular amastigotes (xRFICI = 0.58)
but additive (no interaction) against BT forms (xRFICI = 1.27)
(Figure 3).
Ultrastructural changes after treatment with NPD-040
In order to visualize the early ultrastructural damage triggered by
NPD-040, electron microscopy analyses were conducted using BTs
of the Y strain (treated for 2 h using the corresponding EC50 of
24 h). As seen in Figure 4(a and b), SEM did not reveal major mor-
phological alterations to the morphology as compared with un-
treated BTs, except for a swollen aspect at the posterior end of the
treated parasite. TEM demonstrated early and common insults
related to flagellar pocket dilatation, disruption of Golgi apparatus,
myelin figures and endoplasmic reticulum profiles surrounding
cytoplasmic organelles (Figure 4c–g).
Target validation by measurement of cAMP
In order to validate that NPD-001 and NPD-040 targeted T. cruzi
PDEs, their effects upon the cAMP content of BTs and CC-released
amastigotes were evaluated using concentrations of 2% the EC50
value and 2.5 h of incubation for each compound. Both com-
pounds induced highly significant increases in the intracellular
cAMP levels of BTs (P < 0.001; Figure 5a). Similar levels (P < 0.001)
were observed at longer incubation times (5 h) and higher inhibitor
concentrations (5%) (data not shown). Both inhibitors also stimu-
lated the release of cAMP by BTs into the extracellular medium,
leading to a detectable rise of the cAMP concentration within 2.5 h
(P < 0.001; Figure 5b). For amastigotes, the increase of intracellular
cAMP was somewhat more modest but still significant (P < 0.001;
Figure 5c) and there was no significant increase in the supernatant
medium after 2.5 h (Figure 5d). Thus, BTs and extracellular
amastigotes displayed similar responses after 2.5 h of incubation
with PDE inhibitors at 2% EC50, with the reduced magnitude of the
observed response in amastigotes possibly attributable to the
higher rate of cAMP export found in these forms, as the medium
cAMP level was 6.7-fold higher for amastigotes than for BTs
(Figure 5b and d).
Expression analysis of T. cruzi PDEs
As part of the interpretation of the results with PDE inhibitors, we
investigated the expression levels of all T. cruzi PDEs in the relevant
parasite stages. The confirmed sequences, which deviated mildly
from the reference genome sequence (CL Brener strain) (Figure
S1), were all deposited at GenBank (Table S3). qRT–PCR analysis
was performed with cDNA from BTs, amastigotes and epimasti-
gotes (Figure 6). The results were normalized in each parasite form
according to their PDE-C level expression. The findings show that
all PDEs are expressed in all three parasite forms. In BTs and epi-
mastigotes, the expression level of PDE-A was clearly below that of
the other PDEs. In amastigotes, the expression of PDE-A was very
similar to PDEs B1, C and D, with PDE-B2 expressed at almost twice
the level of the other enzymes. In epimastigotes, PDE-D expression
was the highest, at200% of PDE-C (Figure 6).
Table 1. Activity and selectivity of studied molecules against intracellu-
lar amastigotes from b-galactosidase-transfected Tulahuen strain of





(mean ± SD) pEC50
SI against
L929 cultures
VUF14656 NPD-001 >10 <5 <3.5
VUF14701 NPD-038 >10 <5 ND
VUF14703 NPD-040 7.8 ±1.7 5.11 3.6
VUF14712 NPD-048 >10 <5 ND
VUF14736 NPD-071 >10 <5 ND
VUF14852 NPD-223 9.4 ±0.9 5.02 3
VUF14471 NPD-226 >10 <5 ND
UAMC02797 NPD-343 >10 <5 ND
VUF14877 NPD-1015 6.2 ±2.4 5.21 >32
VUF15404 NPD-1016 5.1±2.3 5.29 >39
VUF15048 NPD-1025 >10 <5 ND
VUF15420 NPD-1043 >10 <5 ND
Benznidazole NPD-1265 2.7 ±0.4 5.57 51
ND, not defined; Corp ID, corporate identification number.
Table 2. In vitro activity and selectivity of the studied molecules against
BTs from the Y strain of T. cruzi incubated for 24 h at 37C
Corp ID Molecule name EC50 lM (mean ± SD) pEC50 SI
VUF14656 NPD-001 9.12±3.37 5.04 5.6
VUF14701 NPD-038 30.29±3.41 4.52 >6.6
VUF14703 NPD-040 12.1±0.8 4.92 >8.3
VUF14712 NPD-048 6.25±0.68 5.20 >32
VUF14736 NPD-071 >200 <3.70 ND
VUF14852 NPD-223 54.47 ±48.91 4.26 >1.8
VUF14471 NPD-226 178±38 3.75 >1.12
UAMC02797 NPD-343 >200 <3.70 ND
VUF14877 NPD-1015 >200 <3.70 ND
VUF15404 NPD-1016 125 ±0 3.90 >1.6
VUF15048 NPD-1025 70.2±9.48 4.15 >2.8
VUF15420 NPD-1043 56.7±4.10 4.25 >3.5
Benznidazole NPD-1265 12.9±1.9 4.3 77
ND, not defined; Corp ID, corporate identification number.
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Discussion
Numerous PDE inhibitors are in current clinical use and some of
these are being pursued as antiparasitic agents through repurpos-
ing.31–33 A sequence alignment of mammalian class I PDEs with
T. brucei PDE-B1 and PDE-B2 first revealed 30%–40% identity34
and led to genetic and pharmacological studies that established
these enzymes as promising drug targets, with the phthalazinone
NPD-001 and its analogues as potent lead compounds.10,13,14,17
In T. cruzi, PDE-C was reported as a pharmacologically validated
drug target11 and we therefore investigated whether the phthala-
zinones also display activity against this trypanosome species.
Phthalazinone derivatives have been studied for decades and
are known for their anti-inflammatory,35,36 anti-aggregating37,38
and antihypertensive39,40 properties. Actually, all these features
are highly connected to their ability to inhibit different PDE iso-
forms, interfering with a large number of biological pathways by
increasing cellular cyclic nucleotide levels.41 In kinetoplastids, cell
cycle regulation6, osmoregulation13 and cytokinesis events10,14,42
are under control of cyclic nucleotide signalling. Moreover, cAMP is
implicated in immune suppression by the infecting parasite.43
Presently, we report the evaluation of NPD-001 and 11 structur-
ally related phthalazinone derivatives against T. cruzi. Four of the
inhibitors were active against intracellular amastigotes (EC50
10 lM), with two of them, NPD-1015 and NPD-1016, fulfilling the
primary criteria of a hit compound for Chagas’ disease (SI 10).29
However, the activity and selectivity of both derivatives were lost
when screened against BTs (the other relevant parasite form for
T. cruzi infection), exhibiting EC50 values in excess of 100 lM.
The lack of corresponding biological activity while assaying both
bloodstream and intracellular forms was also noticed with other
studied phthalazinones such as NPD-223 and some possible
explanations could be raised, including the use of different parasite
strains (Y for BT and Tulahuen for intracellular forms). Another pos-
sibility is the potential impact of PDE inhibitors on the host cell
physiology, indirectly affecting parasite survival. These issues could
result in different potency outcomes for assays with intracellular
and extracellular forms, for reasons of host cell physiology rather
than direct inhibition of parasite PDEs. To address these issues,
amastigotes naturally released by CC cultures were employed, but
now using the Y strain (the same as previously tested on BTs) and
incubations from 24 up to 96 h. Although benznidazole displayed a
remarkably time-dependent trypanocidal effect, the phthalazi-
none NPD-040 sustained a comparatively equivalent action during
the entire incubation period, with the EC50 values between 4.0 and
7.7 lM. These potencies are very similar to those found against
intracellular amastigotes (Tulahuen strain) in L929 cells
(EC50 = 7.8 lM), which argues against any potential difference
related to parasite strain. Additional studies with NPD-001 also
showed a similar potency against amastigotes (22 and 20 lM for
the Tulahuen and Y strain, respectively) regardless of the parasite
DTU and parasite localization (intracellularly or in a cell-free sys-
tem), which disproves the possibility that these phthalazinones act
indirectly on the amastigotes by impacting the host cell metabol-
ism. However, other aspects may be considered including the
metabolic differences of the highly proliferative amastigotes and
the non-dividing but infective BTs, which could influence their dif-
ferent susceptibility to drugs manipulating cAMP.44 Another dis-
tinct possibility would be the differential expression of individual
PDEs in the various lifecycle forms and we did find some evidence
for this, such as with PDE-A and PDE-B2 being somewhat higher
expressed in the amastigote stage than in trypomastigotes. Hard
evidence of which PDE is being targeted will require systematic as-
sessment of the essentiality of each PDE in the various life cycle
stages and inhibitor studies on each separate enzyme.
Some differences in susceptibility according to parasite form
may be attributable to the ability of the host cells to take up or ex-
trude the compound. For instance, NPD-048 displayed higher EC50
values for intracellular amastigotes of T. cruzi, regardless of parasite
strain (12 and 18 lM), than against extracellular parasites (BTs and
extracellular amastigotes: 6.2 lM for both), suggesting that pene-
tration of the mammalian host cell may be limiting its efficacy.
A further factor in differential activity against amastigotes and
BTs could be the observation that amastigotes seem to release
cAMP much faster and in higher levels than BTs, which might make
them less vulnerable to PDE inhibition. In both BTs and amasti-
gotes, the levels of cAMP in intracellular contents increased rapidly
in the presence of PDE inhibitors and were highly significantly ele-
vated at the 2.5 h point, reminiscent of a recent study on T. cruzi
that reported a high and very rapid (2 h) increase in cAMP levels
under the nutritional stress conditions that trigger metacyclogene-
sis.45 The genome of trypanosomatids encodes five different
isoforms of PDEs33,46 and we report the cloning and sequencing of
all the PDE genes for the Y and Colombiana strains, and their
relative level of expression in amastigotes, BTs and epimastigotes.
The cAMP measurements clearly show that, like T. brucei,14 T. cruzi
regulates its intracellular cAMP level in two ways: (i) degradation
by PDEs; and (ii) extrusion to the extracellular environment, which
in mammalian cells is mediated by ATP-binding cassette (ABC)
transporters.47,48 The cAMP concentration in the extracellular me-
dium of untreated amastigote suspensions was 6.7-fold higher
than in the untreated trypomastigote suspension, reflecting a
much higher rate of natural basal efflux by untreated amastigotes
and this allows the untreated amastigotes to maintain the same
steady-state intracellular cAMP concentration as the untreated
trypomastigotes (22.6±1.1 versus 23.3±1.7 lM, values normalized
according to each cellular volume; P > 0.05; Figure 5). As the overall
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Figure 2. Kinetic profile of NPD-040 activity upon extracellular amasti-
gotes of the Y strain, following 24, 48 and 96 h of treatment.
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vary modestly in the various isoforms, it appears that cAMP
production, signalling and efflux are likely much more active in
amastigotes. Thus, for the two inhibitors tested here, cAMP accu-
mulation in BTs reached substantially higher concentrations than
in amastigotes, due to their lower capacity for efflux, as evidenced
by the much lower extracellular levels in the trypomastigote
suspension.
T. cruzi PDEs have previously been implicated in osmotic con-
trol.49 As initially observed by light microscopy (data not shown),
BT forms exposed to NPD-040 display a swollen morphological as-
pect, which was clearly observed by SEM, even after short periods
of compound incubation, and may reflect an altered osmotic bal-
ance. The ultrastructural analysis performed by TEM showed that
this phthalazinone rapidly causes damage to the Golgi and the
flagellar pocket and induces membranous profiles surrounding
intracellular organelles that resemble autophagy, as already
reported for other trypanocidal agents,50,51 and this merits further
investigation.
Combination therapy is a valuable tool to improve treatment
efficacy by reducing dose levels and toxicity and preventing
the development of drug resistance.52,53 We thus investigated the
merits of a combination of benznidazole and NPD-040. Although
for BTs the xRFICI value of 1.27 indicated no interaction (additive
profile), for intracellular forms a close-to-synergistic response
was obtained (xRFICI = 0.58). The distinct profile could be related
to differences of metabolic states of replicating amastigotes and
non-dividing trypomastigotes, respectively. Considering that in
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Figure 3. In vitro compound interactions of NPD-040 and benznidazole upon T. cruzi, using a fixed-ratio method on intracellular forms of Tulahuen
strain (a) and BTs of the Y strain (b). Dose–response experiments were performed with NPD:BZ at 5:0, 4:1, 3:2, 2:3, 1:4 and 0:5 fixed ratios, using the
predetermined EC50 values to establish the top concentrations.
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Figure 4. Electron microscopy of a BT of T. cruzi (Y strain), untreated (a and c) and exposed for 2 h to NPD-040 (b and d–g) and evaluated by SEM (a
and b) and TEM (c–g). Parasites treated with NPD-040 displayed flagellar pocket dilatation (filled circle), disruption of Golgi apparatus (filled square),
myelin figures (open circle) and endoplasmic reticulum profiles (open square) surrounding cytoplasmic organelles. PM, plasma membrane; GC, Golgi
complex; ER, endoplasmic reticulum; F, flagellum; M, mitochondria; N, nuclei.
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through the inhibition of cytokinesis,14 the lesser effect of (some)
PDE inhibitors on the non-dividing trypomastigotes may not be
that surprising.
Human PDEs have a long history as drug targets and several
inhibitors already on the market are used for a wide spectrum of
clinical conditions.54 Hence, extensive experience in the clinical
development of PDE inhibitors is available and this may help to de-
velop parasite-selective inhibitors. Issues related to the specificity
can be overcome through medicinal chemistry guided by crystal
structures.8,15 Knowledge transfer from the field of human PDE
inhibitors, together with a collaborative, multidisciplinary approach
to drug discovery, provides new opportunities to couple the
curiosity-driven research culture in academia with the stringent
preclinical practices used in industry.55 In this way, the cumulative
knowledge and skill of the private and academic sectors may be
employed for drug discovery programmes focused on neglected
pathologies like Chagas’ disease, which has millions of patients
waiting for safer and more effective therapies.
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content samples are displayed in graphs (a) and (c), while values for
extracellular medium samples are shown in graphs (b) and (d).
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36 Van der Mey M, Bommelé KM, Boss H et al. Synthesis and structure-
activity relationships of cis tetrahydrophthalazinone/pyridazinone hybrids: a
novel series of potent dual PDE3/PDE4 inhibitory agents. J Med Chem 2003;
46: 2008–16.
37 Tanaka K, Harada Y, Iwata M et al. Potentiation of anti-aggregating
activity of PGI2 by 7-ethoxycarbonyl-6,8-dimethyl-4-hydroxymethyl-1(2H)-
phthalazinone (EG-626) in rabbit platelets in vitro. Prostaglandins 1980; 20:
255–68.
38 Sugimoto A, Sakamoto K, Fujino Y et al. Synthesis and inhibitory effect on
platelet aggregation of 2-phenyl-1(2H)-phthalazinone derivatives. Chem
Pharm Bull (Tokyo) 1985; 33: 2809–20.
39 Demirayak S, Karaburun AC, Beis R. Some pyrrole substituted aryl pyrida-
zinone and phthalazinone derivatives and their antihypertensive activities.
Eur J Med Chem 2004; 39: 1089–95.
40 Del Olmo E, Barboza B, Ybarra MI et al. Vasorelaxant activity of
phthalazinones and related compounds. Bioorg Med Chem Lett 2006;
16: 2786–90.
41 Herman AG. Rationale for the combination of anti-aggregating drugs.
Thromb Res 1998; 92 Suppl 1: S17–21.
42 Salmon D, Bachmaier S, Krumbholz C et al. Cytokinesis of Trypanosoma
brucei bloodstream forms depends on expression of adenylyl cyclases of the
ESAG4 or ESAG4-like subfamily. Mol Microbiol 2012; 84: 225–42.
43 Salmon D, Vanwalleghem G, Morias Y et al. Adenylate cyclases of
Trypanosoma brucei inhibit the innate immune response of the host. Science
2012; 337: 463–6.
44 Brunoro GV, Caminha MA, Ferreira AT et al. Reevaluating the
Trypanosoma cruzi proteomic map: the shotgun description of bloodstream
trypomastigotes. J Proteomics 2015; 115: 58–65.
45 Hamedi A, Botelho L, Britto C et al. In vitro metacyclogenesis of
Trypanosoma cruzi induced by starvation correlates with a transient adenylyl
cyclase stimulation as well as with a constitutive upregulation of adenylyl
cyclase expression. Mol Biochem Parasitol 2015; 200: 9–18.







/jac/article/75/4/958/5682465 by Vrije U
niversiteit Am
sterdam
 user on 14 January 2021
46 Makin L, Gluenz E. cAMP signalling in trypanosomatids: role in pathogen-
esis and as a drug target. Trends Parasitol 2015; 31: 373–9.
47 Godinho RO, Duarte T, Pacini ES. New perspectives in signaling mediated
by receptors coupled to stimulatory G protein: the emerging significance of
cAMP efflux and extracellular cAMP-adenosine pathway. Front Pharmacol
2015; 6: 58.
48 Cheepala S, Hulot JS, Morgan JA et al. Cyclic nucleotide compartmental-
ization: contributions of phosphodiesterases and ATP-binding cassette trans-
porters. Annu Rev Pharmacol Toxicol 2013; 53: 231–53.
49 Docampo R, Jimenez V, King-Keller S et al. The role of acidocalcisomes in
the stress response of Trypanosoma cruzi. Adv Parasitol 2011; 75: 307–24.
50 Vannier-Santos MA, De Castro SL. Electron microscopy in antipara-
sitic chemotherapy: a (close) view to a kill. Curr Drug Targets 2009; 10:
246–60.
51 Fonseca-Berzal C, Da Silva CF, Menna-Barreto RF et al. Biological
approaches to characterize the mode of action of two 5-nitroindazolinone
prototypes on Trypanosoma cruzi bloodstream trypomastigotes. Parasitology
2016; 143: 1469–78.
52 Diniz L de F, Urbina JA, de Andrade IM et al. Benznidazole and posacon-
azole in experimental Chagas disease: positive interaction in concomitant
and sequential treatments. PLoS Negl Trop Dis 2013; 7: e2367.
53 De Koning HP. Drug resistance in protozoan parasites. Emerg Top Life Sci
2017; 1: 627–32.
54 Abusnina A, Lugnier C. Therapeutic potentials of natural compounds act-
ing on cyclic nucleotide phosphodiesterase families. Cell Signal 2017; 39:
55–65.
55 Dahlin JL, Inglese J, Walters MA. Mitigating risk in academic preclinical
drug discovery. Nat Rev Drug Discov 2015; 14: 279–94.







/jac/article/75/4/958/5682465 by Vrije U
niversiteit Am
sterdam
 user on 14 January 2021
